This model captured key steps of the cancer immunity cycle and enabled a ‘condensed’ representation of the immunosuppressive components of the TME, as a lumped function of molecular and cellular events affected by treatment(s) (e.g., PD-L1- and A2AR-mediated pathways) or not explicitly modulated by treatment(s) (e.g., presence of Tregs). Here, ADORA2A is linked to cancer.